Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

quantum physics

- PMLiVE

Moderna’s booster vaccine for South African variant demonstrates promising early results

Booster vaccine candidate increase neutralising titers against SARS-CoV-2 variants of concern in preclinical study

Shaping the Future of Medicine, Science, and Technology

Dr. José Morey, CEO and Founder of Ad Astra Media, Chief Medical Innovation Officer at Liberty BioSecurity, and the world’s first “intergalactic doctor” discusses AI, space medicine, human augmentation, and...

Impetus Digital

- PMLiVE

Keytruda plus chemotherapy gains US approval for advanced oesophageal cancer

First checkpoint inhibitor to win approval in the first-line setting for this cancer type

- PMLiVE

NICE rejects Keytruda for advanced bladder cancer in final guidance

Treatment had been authorised for use in this indication via the Cancer Drugs Fund in 2018

- PMLiVE

Merck & Co signs deal with Amathus for neurodegenerative diseases

Collaboration will focus on developing small molecules for undisclosed disease targets

- PMLiVE

Moderna launches COVID-19 vaccine booster study to address new variants

First participants receive company’s modified vaccine candidates

- PMLiVE

Researchers use AI to identify drugs that could be repurposed for Alzheimer’s

Eli Lilly's JAK inhibitor Olumiant identified as a potential treatment for repurposing

- PMLiVE

Merck & Co, Ridgeback Biotherapeutics’ COVID-19 drug shows early promise

Molnupiravir led to a faster decrease in infectious virus among participants with early COVID-19

- PMLiVE

Merck & Co to help produce J&J’s COVID-19 vaccine in the US

Company has signed agreements to bolster vaccine manufacturing capacity

- PMLiVE

MSD withdraws Keytruda’s US indication for small cell lung cancer

Checkpoint inhibitor gained accelerated approval in 2019

- PMLiVE

AZ sells stake in Moderna for around $1.2bn

As Moderna expects COVID-19 vaccine sales to reach $18.4bn this year

- PMLiVE

Merck to acquire Pandion Therapeutics for $1.85bn

Merck will gain a pipeline of immune modulators targeting autoimmune diseases

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links